Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1990 1
1994 8
1995 2
1996 4
1997 7
1998 2
2001 3
2002 1
2010 1
2011 4
2012 2
2013 2
2014 3
2015 1
2016 1
2017 1
2019 2
2020 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Results by year

Filters applied: . Clear all
Page 1
A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries.
Belkacemi Y, Grellier N, Ghith S, Debbi K, Coraggio G, Bounedjar A, Samlali R, Tsoutsou PG, Ozsahin M, Chauvet MP, Turkan S, Boussen H, Kuten A, Tesanovic D, Errihani H, Benna F, Bouzid K, Idbaih A, Mokhtari K, Popovic L, Spano JP, Lotz JP, Cherif A, To H, Kovcin V, Arsovski O, Beslija S, Dzodic R, Markovic I, Vasovic S, Stamatovic L, Radosavljevic D, Radulovic S, Vrbanec D, Sahraoui S, Vasev N, Stojkovski I, Risteski M, Freixa SV, Krengli M, Radosevic N, Mustacchi G, Filipovic M, Kerrou K, Taghian AG, Todorovic V, Geara F, Gligorov J. Belkacemi Y, et al. Among authors: kovcin v. Eur J Cancer. 2020 Aug;135:130-146. doi: 10.1016/j.ejca.2020.05.015. Epub 2020 Jun 8. Eur J Cancer. 2020. PMID: 32580130 Free PMC article. Review.
RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer.
Spigel DR, Dowlati A, Chen Y, Navarro A, Yang JC, Stojanovic G, Jove M, Rich P, Andric ZG, Wu YL, Rudin CM, Chen H, Zhang L, Yeung S, Benzaghou F, Paz-Ares L, Bunn PA; RESILIENT Trial Investigators. Spigel DR, et al. J Clin Oncol. 2024 Apr 22:JCO2302110. doi: 10.1200/JCO.23.02110. Online ahead of print. J Clin Oncol. 2024. PMID: 38648575
[Pancreatic carcinoma: from genes to therapy].
Andrić Z, Pjević J, Radosavljević V, Kovcin V, Milićević N, Petrović N. Andrić Z, et al. Among authors: kovcin v. Srp Arh Celok Lek. 2001 Nov-Dec;129(11-12):328-33. Srp Arh Celok Lek. 2001. PMID: 11928620 Review. Serbian. No abstract available.
Multivariate analysis of prognostic factors in male breast cancer in Serbia.
Sipetic-Grujicic SB, Murtezani ZH, Neskovic-Konstatinovic ZB, Marinkovic JM, Kovcin VN, Andric ZG, Kostic SV, Ratkov IS, Maksimovic JM. Sipetic-Grujicic SB, et al. Among authors: kovcin vn. Asian Pac J Cancer Prev. 2014;15(7):3233-8. doi: 10.7314/apjcp.2014.15.7.3233. Asian Pac J Cancer Prev. 2014. PMID: 24815476 Free article.
Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.
Hanna NH, Kaiser R, Sullivan RN, Aren OR, Ahn MJ, Tiangco B, Voccia I, Pawel JV, Kovcin V, Agulnik J, Gaschler-Markefski B, Barrueco J, Sikken P, Schloss C, Kim JH; LUME-Lung 2 Study group. Hanna NH, et al. Among authors: kovcin v. Lung Cancer. 2016 Dec;102:65-73. doi: 10.1016/j.lungcan.2016.10.011. Epub 2016 Oct 27. Lung Cancer. 2016. PMID: 27987591 Clinical Trial.
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X; SafeHer Study Group. Gligorov J, et al. Eur J Cancer. 2017 Sep;82:237-246. doi: 10.1016/j.ejca.2017.05.010. Epub 2017 Jun 16. Eur J Cancer. 2017. PMID: 28625777 Clinical Trial.
Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non-Small-Cell Lung Cancer (GALAXY-2).
Pillai RN, Fennell DA, Kovcin V, Ciuleanu TE, Ramlau R, Kowalski D, Schenker M, Yalcin I, Teofilovici F, Vukovic VM, Ramalingam SS. Pillai RN, et al. Among authors: kovcin v. J Clin Oncol. 2020 Feb 20;38(6):613-622. doi: 10.1200/JCO.19.00816. Epub 2019 Dec 12. J Clin Oncol. 2020. PMID: 31829907 Clinical Trial.
AROME-ESO Oncology Consensus Conference: access to cancer care innovations in countries with limited resources. Association of Radiotherapy and Oncology of the Mediterranean Area (AROME-Paris) and European School of Oncology (ESO - Milan).
Todorovic V, Aapro M, Pavlidis N, Arsovski O, Belkacemi Y, Babovic N, Bidard FC, Bourhafour M, Beslija S, Boussen H, Cetnikovic B, Ceric T, Cicmil N, Crnogorac N, Cuedari E, De Laurentis M, Dragovich T, Durutovic I, Dzamic Z, Dzodic R, Eri Z, Geara F, Khalil A, Kerrou K, Knezevic Usaj S, Kovcin V, Koroveshi D, Kristo Pema A, Kuten A, Lakicevic J, Lukovac N, Markovic I, Markovic M, Mijalkovic N, Miladinova D, Milasevic N, Mustachi G, Ognjenovic D, Pantelic A, Popovic L, Radosavljevic D, Radosevic N, Radulovic S, Ristevski M, Rosic I, Secen N, Sorat M, Stamatovic L, Stefanovski P, Stojkovski I, Tesanovic D, Tomasevic Z, Tomasevic Z, Tsoutsou P, Turkan S, Vasev N, Vasovic S, Vicko F, Vrbanec D, Vukmirovic F, Vrdoljak E, Zaric B, Zambrovski JJ, Cavalli F, Gligorov J. Todorovic V, et al. Among authors: kovcin v. J BUON. 2019 Sep-Oct;24(5):2180-2197. J BUON. 2019. PMID: 31786893 Free article.
47 results